Back to search
FDAFDA · Food and drugs·Recall number Z-0601-2019

Hemoglobin A1c Control, Part no. 220232 for use as quality control material to monitor the precision of laboratory testing procedures for HbA1c quantitation.

Published December 19, 2018 · Recall initiated: October 5, 2018

Summary

FDA records medical device Class III recall Z-0601-2019, published December 19, 2018 and initiated October 5, 2018. Recalling firm: Tosoh Bioscience Inc; Status: Terminated; Reported quantity: 1000; Lot: Lot 7055. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Tosoh Bioscience has become aware of potential degradation of HbA1c control lot # 7055 before the 60-days product stability claim. If degradation of these controls occurs, P00 peaks may be seen and the % HbA1c control values may drift higher than the assigned range. This may result in delays when performing routine instrument quality control. If this issue occurs, there may be a delay in testing and reporting patient test results. Tosoh has received two (2) complaints related to this issue with no serious injuries reported.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Tosoh Bioscience Inc
Distributor
Distributed nationwide. Foreign distribution to Canada.
Lot
Lot 7055
Risk classification
Class III
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was Hemoglobin A1c Control, Part no. 220232 for use as quality control material to monitor the precision of laboratory testing procedures for HbA1c quantitation. recalled?

Yes. FDA published recall Z-0601-2019 on December 19, 2018. Reported hazard: Tosoh Bioscience has become aware of potential degradation of HbA1c control lot # 7055 before the 60-days product stability claim. If degradation of these controls occurs, P00 peaks may be seen and the % HbA1c control values may drift higher than the assigned range. This may result in delays when performing routine instrument quality control. If this issue occurs, there may be a delay in testing and reporting patient test results. Tosoh has received two (2) complaints related to this issue with no serious injuries reported.

What should I do if I have this product?

Voluntary: Firm initiated · Letter